PARP1 and neoplasm: Molecular mechanisms that have been associated with the development of resistance to PARP inhibitors include up-regulation of the p-glycoprotein efflux pump, PARP overexpression as well as a shift in the BRCA mutational reading frame, which may explain why not all BRCA-mutated tumours are sensitive to PARP inhibition [7].